Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. (GV) operates at the intersection of education and technological innovation, with expanding ventures in life sciences and sustainable energy solutions. This news hub provides investors and industry observers with comprehensive updates on the company’s strategic developments across all operational sectors.
Access real-time announcements covering AI education initiatives, biotech research breakthroughs, new energy vehicle developments, and global partnership expansions. Our curated collection ensures you stay informed about earnings reports, leadership updates, and technological advancements without needing to monitor multiple sources.
Key updates include regulatory filings, academic program launches, research collaborations, and progress in digital asset tokenization projects. Each piece of content is verified for accuracy and relevance to maintain your competitive edge in understanding this multifaceted organization.
Bookmark this page for streamlined access to Visionary Holdings’ evolving story. Return regularly to track how the company continues bridging educational excellence with cutting-edge technological applications across diverse industries.
Visionary Holdings (Nasdaq: GV) received a Nasdaq Listing Qualifications notice for failure to timely file its Annual Report on Form 20-F for the fiscal year ended March 31, 2025. The notice, dated August 5, 2025, cites noncompliance with Nasdaq Listing Rule 5250(c)(1) but has no immediate effect on the listing or trading of the company's common shares on the Nasdaq Capital Market. The company had a 60-calendar-day period to submit a compliance plan and filed that plan on October 6, 2025. Visionary says it is working with its independent auditor to complete the audit and file the Form 20-F as soon as possible and remains committed to restoring full reporting compliance and maintaining its Nasdaq listing.
Visionary Holdings (Nasdaq: GV) announced on October 22, 2025 a strategic cooperation with Jiangsu Yike to form Visionary Yike Stemcell Technologies, a Canada-based joint venture focused on stem cell R&D, clinical application, manufacturing and global commercialization.
GV will hold 85% and Yike 15%. The JV may be headquartered at GV's Toronto property (95–105 Moatfield Drive, ~40,000 sqm) and will explore cleanrooms, low-temperature biostorage, and production infrastructure. Initial targets include stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics with a stated focus on Type 1 and Type 2 diabetes; clinical evidence so far is described as preclinical/exploratory. Development is subject to regulatory, financing, and operational planning.
Visionary (Nasdaq: GV) completed an equity adjustment on Oct 17, 2025 and obtained a 51% controlling stake in Sikang (Guangzhou) Health Industry Investment, turning a prior strategic cooperation into capital-driven control.
The move aims to combine Visionary's global capital channels with Guangzhou Sikang's TCM operating ecosystem to scale standardized TCM health preservation services domestically and internationally, including September 22, 2025 market entry in Malaysia and an October 7, 2025 Panyu cooperation conference with over 200 partners.
Forward-looking risks cited include changes in global demand, cross-border compliance adjustments, intensified competition, and potential operational inefficiencies.
Visionary Holdings (Nasdaq: GV) announced on October 13, 2025 that its subsidiary secured a global product and technology licensing agreement with Jiangsu Yike Regenerative Medicine, granting GV worldwide rights to Yike's stem cell technology platform.
The collaboration targets stem cell therapies for Type 1 and Type 2 diabetes, anti‑aging biological repair, and cellular rejuvenation, with clinical trials said to show potential for long‑term remission and possible complete cure. The deal uses a revenue‑sharing model: Yike focuses on licensing and clinical R&D while GV provides global commercialization, clinical channels, and brand operations. The announcement cites a >$150 billion global diabetes treatment market and 540 million affected adults as strategic opportunity.
Visionary Holdings (GV) mailed its Notice of Meeting and Management Information Circular to shareholders of record as of September 12, 2025 for the 2025 Annual Meeting to be held on October 29, 2025 at 10:00 a.m. ET at 19 W 26th St, 5th Fl, New York, NY, with remote attendance via ZOOM.
Agenda items include: electing nine directors, ratifying Assentsure PAC as auditors for the year ended March 31, 2025, and other business. The Company will file its Annual Report on Form 20-F for the year ended March 31, 2025 with the SEC and will provide copies on request.
Voting options: return the Proxy Card, vote in person, or follow the stated online/email procedures (email: lowelltoronto@hotmail.com). Record shareholder list available for inspection 10 days before the meeting. A single holder, 3888 Investment Group, holds 1,516,668 Class B shares (~26.49% of shares) and Class B shares carry 100 votes each (~97.30% of voting power).
Visionary Holdings (Nasdaq: GV) has announced a strategic partnership between its subsidiary Visionary Holdings (Asia) Limited and Qianxin Bocheng, a Jiangsu-based industrial park operator and accelerator. The three-year agreement focuses on advancing the aesthetic treatment industry through four key initiatives:
The collaboration encompasses industrial park development, project incubation, enterprise cultivation with M&A opportunities, and brand promotion activities. Qianxin Bocheng will provide policy support, funding, and facilities, while Visionary Holdings will contribute operational expertise, capital resources, and international experience.
A joint working group will be established to oversee implementation and strategic decision-making. The partnership aims to create an integrated model combining industry, capital, and policy support to foster innovation in the aesthetic treatment sector.
Visionary Holdings (NASDAQ:GV) has announced a strategic partnership with Jiangsu Yike Regenerative Medicine to enter the cellular rejuvenation and aesthetic treatment market. Under the agreement, Yike will lead and fund R&D efforts, while GV may acquire or license the resulting intellectual property through cash or share payments.
The collaboration focuses on three core areas: Cell Activation and Telomerase Homeostasis, utilizing Yike's proprietary Cell-Activating Complex; Smart Delivery and Personalized Solutions, leveraging Nano-Delivery™ technology; and Stem Cell and Immune Cell Applications for aesthetic and healthcare innovations. The partnership will be supported by renowned aging expert Dr. Zhenyu Ju, Yike's Chief Scientist and Dean of the Institute of Aging and Regenerative Medicine at Jinan University.
Visionary Holdings' subsidiary Changle Shuang has formed a strategic partnership with the Guangzhou Jianjia Charity Foundation to launch a nationwide free Helicobacter pylori (Hp) screening campaign in China. The initiative, titled "Healthy Stomach Future, Early Screening for Peace of Mind," aims to provide free Hp testing services to 10 million users.
The campaign addresses a significant health concern in China, where Hp infection rates range from 40%-60%, with 70% of infected individuals showing no obvious symptoms. Changle Shuang, specializing in gastrointestinal microecology nutrition and health, will contribute its patented probiotic technology and professional services to support the screening program.
Visionary Holdings (GV) has announced critical changes to its digital infrastructure following a malicious IT attack that compromised their original website and email systems. The company reported that their previous website (www.visiongroupca.com) and corporate email (@farvision.ca) were hacked, leading to complete system breakdown and potential data security risks.
In response, the company has immediately deactivated these compromised channels and launched new official communication platforms: website www.visionary.holdings and corporate email suffix @visionary.holdings. All stakeholders are required to update their contact information and re-verify cooperation details through the new website.
FAQ
What is the current stock price of Visionary Holdings (GV)?
What is the market cap of Visionary Holdings (GV)?
